Endpoints and demonstrate the Idarubicin Idamycin clinical value of 8 mg fesoterodine to patients for an escalation of the h Chsten dose fesoterodine decide to be approved is likely to achieve an improvement in symptoms My best to approve the patient treated with the h Chsten dosage of tolterodine ER. The current results are also consistent with a post-hoc analysis of a phase III study that included tolterodine ER than fesoterodine contr The Net Assets Assets value, which resulted in a significantly gr Ere improvement in UUI episodes and micturition by MVV with, fesoterodine 8 mg compared with tolterodine ER 4 mg. In this study, was superior to tolterodine, fesoterodine 8 mg ER 4 mg every other study parameters, except n Nocturnal urination, as early as week 4, or 3 weeks after Dosiserh Increase of 8 mg fesoterodine. There were no significant differences between fesoterodine 4 mg and tolterodine ER 4 mg in week 1 However, fesoterodine 4 mg was associated with statistically significant improvements in all parameters of the study compared to placebo at week 1, w While tolterodine ER 4 mg was associated with statistically significant improvements in UUI episodes and CBPP and UPS scores for placebo at week 1 compared. The apparent efficacy of fesoterodine 4 mg early and 4 mg of tolterodine ER is important for symptoms of overactive bladder, because these symptoms are often l Stig and can have negative effects on health Lebensqualit t. The expected efficacy at 1 week of treatment has already been demonstrated for tolterodine ER and other antimuscarinics. Both this study and the former leader of the study showed that 8 mg fesoterodine significantly gr head Ere improvements than tolterodine ER 4 mg and placebo on several subjective estimations phone start-up, Self-reported severity of symptoms produced and the impact of OAB symptoms on these topics The life of confinement The Lich Ma Took the symptom St rt Me, health Lebensqualit t, the urgency and seriousness of the global problems associated with the bladder. In addition, fesoterodine 8 mg h significantly associated with an improvement Ago as tolterodine ER 4 mg of the benefits as early as week 4, the results of the evaluations are associated newspaper parallels in this study. These results are exciting because they suggest that the superiority of fesoterodine 8 mg tolterodine ER 4 mg in improving bladder diary variables, differences in efficiency, which are clinically significant in patients with overactive bladder reflection. Both active treatments were generally well tolerated in this study. The appearance of the rule h Her treatment of side effects in the group of 8 mg fesoterodine over tolterodine ER 4 mg and placebo groups in the first place by a increased Hte incidence of dry mouth and may be on the design of the study where dose escalation was not optional, why be attributed, the dose of fesoterodine in patients for the 4 mg is the optimal dose of fesoterodine have intensified. A m Restrict Possible LIMITATION this study was that the concentrated dose escalation is not optional for patients on fesoterodine, but this survey on maximum doses of each agent is available. Whereas the use of the h Chsten available dose of each active treatment was appropriate to show in this study for superiority, this may not directly reflect clinical practice. With a flexible dose in patients who achieve sufficient efficacy of fesoterodine 4 mg, or dose-limiting toxicities escalatio.